In contrast, in chronic myeloid leukemia, the initiating event is represented by BCR-ABL, while in several other myeloid cancers the initiating events are PDGFR translocations, so therapy in those cases would target in the initiating events. The gene discussed is PDGFRB; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.